



Opioid Risk Management
Tuesday, March 29, 2005
The Colonnade Hotel
Boston, Mass.



Agenda

Meeting Chair: Nathaniel Katz, MD, MS

7:00 a.m. **Breakfast and registration**

8:00 a.m. **Welcome and overview**
Daniel Carr, MD
Nathaniel Katz, MD, MS
Tufts University School of Medicine

<p>Perspectives of Major Stakeholders on Opioid Risk Management</p>
--

8:15 a.m. **National Institute of Drug Abuse (NIDA) perspective on prescription opioid abuse**
Wilson M. Compton, MD, MPE
Director, Division of Epidemiology, Services and Prevention Research
National Institute on Drug Abuse

8:35 a.m. **Discussion**

8:45 a.m. **FDA Perspective on opioid risk management**
Bob Rappaport, MD
Director, Division of Anesthetic, Critical Care, and Addiction Drug Products
Deborah Leiderman, MD
Director, Controlled Substances Staff

9:05 a.m. **Discussion**

9:15 a.m. **DEA perspective on opioid risk management**
Patricia Good
Office of Diversion Control
Drug Enforcement Administration

9:35 a.m. **Discussion**



Opioid Risk Management



Agenda, continued

-
- 9:45 a.m. **The role of SAMHSA in prescription opioid abuse**
 Judy K. Ball, PhD, MPA
 Drug Abuse Warning Network
 Office of Applied Studies
 Substance Abuse & Mental Health Services Administration
- 9:55 a.m. **Discussion**
- 10:15 a.m. **Break**
- 10:30 a.m. **The role of electronic prescription monitoring in opioid risk management**
 Grant Carrow, PhD
 Director, Drug Control Program
 Massachusetts Department of Public Health
- 10:50 a.m. **Discussion**
- 11:00 a.m. **Industry perspective on opioid risk management**
 Marie Pinizzotto, MD
 Senior Director, Global Safety and Pharmacovigilance
 Endo Pharmaceuticals
- 11:20 a.m. **Discussion**
- 11:30 a.m. **Balance in policy related to opioid risk management**
 David Joranson, MSW
 Director, Pain and Policy Studies Program
 University of Wisconsin
- 11:50 a.m. **Discussion**
- 12:00 p.m. **Lunch**
- 12:30 p.m. Lunchtime discussion: Interventions to reduce prescription opioid abuse

Update on Prescription Opioid Abuse Surveillance

- 1:00 p.m. **History and future of drug abuse surveillance**
 Edgar H. Adams, ScD
 Senior Vice President of Clinical Research and Risk Management
 Harris Interactive



Opioid Risk Management



Agenda, continued

-
- 1:20 p.m. **Discussion**
- 1:30 p.m. **Key informant networks: scientific update**
Theodore Cicero, PhD
Vice Chancellor for Research
Washington University in St. Louis
- 1:50 p.m. **Discussion**
- 2:00 p.m. **New Approaches in Prescription Opioid Abuse Surveillance**
NAVIPPRO: An emerging surveillance system
Simon H. Budman, PhD
Assistant Clinical Professor of Psychology
Department of Psychiatry, Harvard Medical School
President and CEO, Inflexxion
- 2:10 p.m. **Inflexxion, Inc. Signal detection in surveillance: scientific update**
James C. Benneyan, PhD
Associate Professor
Northeastern University
- 2:30 p.m. **Discussion**
- 2:40 p.m. **Break**

Approaches to Reducing Prescription Opioid Abuse: Understanding and Intervention

- 3:00 p.m. **Prescription drug diversion**
James Inciardi, PhD
Professor
University of Delaware, Center for Alcohol and Drug Studies
- 3:10 p.m. **Discussion**
- 3:20 p.m. **Development of abuse-resistant opioid formulations**
William K. Schmidt, PhD
Vice President of Clinical Research
Renovis, Inc.
- 3:40 p.m. **Discussion**



Opioid Risk Management



Agenda, continued

- 3:50 p.m. **Opioid risk management at the patient level: universal precautions**
Douglas Gourlay, MD, FRCPC, FASM
University of Toronto
- 4:00 p.m. **Discussion**
- 4:10 p.m. **The role of supply chain integrity in opioid risk management**
Ron Buzzeo, RPh
President
BuzzeoPDMA, Inc.
- 4:20 p.m. **Discussion**
- 4:30 p.m. **Cost of prescription opioid abuse**
Howard Birnbaum, PhD
Co-Director, Health Care Economics Practice
Vice President, Boston
Analysis Group
- 4:40 p.m. **Discussion**
- 4:50 p.m. **Meeting summary and conclusion**
Nathaniel Katz, MD, MS
- 5:00 p.m. **Adjourn**